enoxaparin and aspirin

Additive anti-haemostatic effect: enoxaparin potentiates antithrombin III-mediated inhibition of factor Xa and thrombin, while aspirin irreversibly inhibits platelet cyclo-oxygenase 1, reducing thromboxane A2 production and impairing platelet aggregation. Co-administration results in complementary inhibition of both the coagulation cascade and platelet function, increasing bleeding risk.

Patients receiving both drugs have an increased risk of haemorrhage, particularly gastrointestinal bleeding, intracranial haemorrhage, and bleeding at surgical sites. The combination may also increase the risk of spinal or epidural haematoma when neuraxial anaesthesia is used. Bleeding can be severe and potentially life-threatening, especially in older patients, those with renal impairment, or those receiving other anticoagulant or antiplatelet agents.

Use with caution and only if clearly indicated. Consider alternatives such as clopidogrel or other antiplatelets if antiplatelet therapy is necessary, or consider non-steroidal anti-inflammatory drugs with lower gastrointestinal bleeding potential, but note that all NSAIDs can increase bleeding risk. When co-prescribed, monitor for signs of bleeding, including occult blood loss, and check haemoglobin, haematocrit, and platelet counts periodically. Consider gastroprotective agents such as proton pump inhibitors to reduce gastrointestinal bleeding risk. Adjust doses and durations of both agents to the minimum necessary. If possible, separate administration times, though this does not eliminate the interaction. Do not use in patients with active bleeding, recent major surgery, or high bleeding risk unless benefit outweighs risk.

The interaction is well established and documented in clinical guidelines, prescribing information, and multiple studies. The combined use of anticoagulants and antiplatelet agents is recognised as a major bleeding risk factor. Evidence includes randomised controlled trials and meta-analyses in cardiovascular and venous thromboembolism settings, as well as pharmacovigilance data. Regional variations exist in clinical practice regarding specific indications and monitoring protocols.